Cardiovascular

Cardiovascular A17 (P346)Severe hypoglycaemia, cardiovascular outcomes and death: Experience from the ‘Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results’ (LEADER) trialS BAIN1, B Zinman2, SP Marso3, E Christiansen4, S Calanna4, S Rasmussen4, and JB Buse51School of Medicine, University of Swansea, Swansea, UK, 2Lunenfeld–Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Canada, 3Research Medical Center, Kansas City, Missouri, USA, 4Novo Nordisk A/S, Søborg, Denmark, 5University of North Carolina School of Medicine, Chapel Hill, North Carolina, USAAims: In the LEADER cardiovascular (CV) outcomes trial (N = 9,340; NCT01179048), the risk of both CV events and hypoglycaemia was reduced with liraglutide treatment vs placebo, when added to standard of care, in patients with Type 2 diabetes and high risk for CV disease. This post hoc analysis examines potential associations between severe hypoglycaemia and CV events and death.Methods: We analysed time to first major adverse cardiovascular event ([MACE] CV death, non‐fatal myocardial infarction or non‐fatal stroke), CV death and all‐cause death, comparing patients with/without severe hypoglycaemia, and adjusted for different periods of follow‐up and randomised treatment (time‐dependent covariate Cox regression).Results: A total of 267 patients experienced severe hypoglycaemia (liraglutide n = 114, placebo n = 153; rate ratio 0.69; 95% confidence interval [CI] 0.51 to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetic Medicine Wiley

Cardiovascular

Loading next page...
 
/lp/wiley/cardiovascular-T6rBEiU0Ko
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Diabetic Medicine © 2018 Diabetes UK
ISSN
0742-3071
eISSN
1464-5491
D.O.I.
10.1111/dme.3_13570
Publisher site
See Article on Publisher Site

Abstract

A17 (P346)Severe hypoglycaemia, cardiovascular outcomes and death: Experience from the ‘Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results’ (LEADER) trialS BAIN1, B Zinman2, SP Marso3, E Christiansen4, S Calanna4, S Rasmussen4, and JB Buse51School of Medicine, University of Swansea, Swansea, UK, 2Lunenfeld–Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Canada, 3Research Medical Center, Kansas City, Missouri, USA, 4Novo Nordisk A/S, Søborg, Denmark, 5University of North Carolina School of Medicine, Chapel Hill, North Carolina, USAAims: In the LEADER cardiovascular (CV) outcomes trial (N = 9,340; NCT01179048), the risk of both CV events and hypoglycaemia was reduced with liraglutide treatment vs placebo, when added to standard of care, in patients with Type 2 diabetes and high risk for CV disease. This post hoc analysis examines potential associations between severe hypoglycaemia and CV events and death.Methods: We analysed time to first major adverse cardiovascular event ([MACE] CV death, non‐fatal myocardial infarction or non‐fatal stroke), CV death and all‐cause death, comparing patients with/without severe hypoglycaemia, and adjusted for different periods of follow‐up and randomised treatment (time‐dependent covariate Cox regression).Results: A total of 267 patients experienced severe hypoglycaemia (liraglutide n = 114, placebo n = 153; rate ratio 0.69; 95% confidence interval [CI] 0.51 to

Journal

Diabetic MedicineWiley

Published: Jan 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off